Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (799)	5/17/1999 9:10:00 PM
From: Michael Brody	Read Replies (1) \| Respond to of 2344

SK, What an odd release. "May" increase survival should read "does", and double the survival time sounds like "news" to me. "while the news is GOOD , it isn't unexpected". What exactly were people expecting ? That Theratope toatlly cures Cancer in ALL people for ALL time ? No wonder BIOM can't really rocket at this time with news slants so grossly underplaying what is happening. This needs to change somehow.

To: Silver Knife who wrote (799)	5/17/1999 10:01:00 PM
From: StockMiser	Read Replies (1) \| Respond to of 2344

Lori McLeod always uses this same source for Biomira - some French Canadian brokerage no one has heard of, and the answer is always the same..."this was anticipated". If BLP-25 eliminated all tumors in humans and cured cancer as we know it, Mike Jams would say "BLP-25 appears to function adaquately. It does what it was designed to do, no more, no less. This was anticipated by everyone following the company. We see no fundamental reasons for a change in our valuations at this time." They make Merrill Lynch look like Don King. SM

To: Silver Knife who wrote (799)	5/17/1999 10:09:00 PM
From: KLH	Read Replies (1) \| Respond to of 2344

Reprint of SK Post #531 concerning the same analyst with same DJ Newswire reporter on Mar 31. This guy Jams is really understated. On this post he has a price target of C$5.... now it is under review. He even uses the same qualifications as to "good news" but not "unexpected". <<<< To: LT (530 ) From: Silver Knife Wednesday, Mar 31 1999 10:11PM ET Reply # of 801 "Short-Lived Bump" March 31, 1999 Biomira Up On Phase I Results; Seen As 'Short-Lived Bump' By LORI MCLEOD Dow Jones Newswires TORONTO -- The 4.3% rise in Biomira Inc.'s (BIOM) stock in Toronto Wednesday is probably a "short-lived bump" in response to the release of Phase I clinical trial results for its BLP25 cancer vaccine, Mike Jams, an analyst with Levesque Beaubien Geoffion Inc. in Montreal, told Dow Jones. In Toronto, Biomira's stock is up 0.21 to 5.15 on about 339,000 shares. Jams noted the stock price rise reflects investors' reaction to positive results from the Phase I clinical trial of BLP25 in 14 patients with non-small-cell lung cancer. The company reported the results earlier Wednesday. While this is "good news" for Biomira, the results weren't unexpected, Jams said. He noted the drug is still in the early stages of development, and predicted that Biomira's share price will settle back. Jams said he sees "no reason" to change his one-year price target of C$5 at this time. However, he noted that any time a company moves a product forward successfully it creates value for shareholders. A Biomira spokesman said the trial was completed on time. He noted the study demonstrated what Biomira hoped it would: that the vaccine can be administered safely and triggers an immune system response against cancer cells. Biomira is working with regulatory agencies to determine what type of clinical trials the vaccine will enter next, the spokesman said. The company is "moving along as quickly as possible" and will provide updates on its progress, he added. -By Lori McLeod; 416-943-7800; lori.mcleod@dowjones.ca>>>>> -end- Any comments as to the analyst and his firms position?

To: Silver Knife who wrote (799)	5/17/1999 10:44:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2344

Sounds pretty much, IMHO, that the stock was runup today by day traders at the open(how about a quick run to 17?) then sold off pretty well. Lots of volume certainly. But hey, their name is out in print in the WSJ. That's great, the story spreads. As far as "may" vs. "does", in post Message 9575244 From a chief researcher: 'The use of immunotherapy is more likely to be successful when there is significant reduction in tumor burden,'' added Dr. Sandmaier. ''In advanced disease states, more aggressive therapy combined with therapy to stimulate the patient's own immune system MAY prove to be effective therapy.'' Looks like that are not committing to saying "it works" just yet. Until more data is presented to the FDA and others, it is still a drug in the development phase. This stock is still a BUY on my list, waiting to get some more. Jim